Beranda › Neoplasma Berdasarkan Tipe Histologis › Texas
Uji klinis Neoplasma Berdasarkan Tipe Histologis di Texas
6 studi untuk Neoplasma Berdasarkan Tipe Histologis mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- UT Southwestern Medical Center, Dallas
- The University of Texas M.D. Anderson Cancer Center, Houston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05874921HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
36 Months – 22 Years · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT03911388Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Texas Oncology - Austin Central, Austin
- World Research Link, Baytown
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT06463665A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.